Survival comparison between 2 groups with single ACAs based on ACA emerging time. (A) Survival comparison in patients with ACAs detected at CML diagnosis. (B-C) Survival comparison in patients with ACAs emerging during CML disease. For panels (A) and (C), OS was calculated from the time of CML diagnosis. For panel (B), OS was calculated from the time of ACA emergence.